This is an expanded access study with a total of 300 participants with NET and suspected SSTR
positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study
participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients
referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then
accepted for scanning if clinically appropriate.